Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.46 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13006996 | 1.00 | KMT2A (0.55) | KMT2AALDH1A1MEN1CYP2D6CYP2C19 | |
| SCHEMBL372493 | 1.00 | KMT2A (0.55) | KMT2AALDH1A1MEN1CYP2D6CYP2C19 | |
| SCHEMBL2143897 | 0.98 | KMT2A (0.56) | KMT2AALDH1A1MEN1CYP2D6CYP2C19 | |
| SCHEMBL2143902 | 0.98 | KMT2A (0.56) | KMT2AALDH1A1MEN1CYP2D6CYP2C19 | |
| SCHEMBL12731547 | 0.86 | KMT2A (0.49) | KMT2AALDH1A1MEN1CYP2D6CYP2C19 | |
| SCHEMBL12731472 | 0.86 | KMT2A (0.49) | KMT2AALDH1A1MEN1CYP2D6CYP2C19 | |
| SCHEMBL20697396 | 0.85 | KMT2A (0.50) | KMT2AALDH1A1MEN1OPRL1YTHDC1 | |
| SCHEMBL10320835 | 0.85 | KMT2A (0.50) | KMT2AALDH1A1MEN1YTHDC1RAB9A | |
| SCHEMBL372409 | 0.85 | KMT2A (0.50) | KMT2AALDH1A1MEN1OPRL1YTHDC1 | |
| SCHEMBL2143781 | 0.85 | KMT2A (0.50) | KMT2AALDH1A1MEN1YTHDC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3560499-B1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-1778240-B1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3560499-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-2275107-B1 | Combinations for the treatment of diseases involving cell proliferation | BOEHRINGER INGELHEIM INT (DE) | 2016-10-05 | — | — | EP | disclosed |
| CN-105640874-A | Dihydropteridinone infusion solution having a long shelf life | 贝林格尔·英格海姆国际有限公司 | 2016-06-08 | — | — | CN | disclosed |
| CN-104055778-A | Dihydropteridinones for the treatment of cancer diseases | OEHRINGER INGELHEIM INTERNAT GMBH | 2014-09-24 | — | — | CN | disclosed |
| US-8591895-B2 | Combinations for the treatment of diseases involving cell proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-26 | — | — | US | disclosed |
| CN-101039673-B | Combinations for the treatment of diseases involving cell proliferation | BOEHRINGER INGELHEIM INT | 2013-10-16 | — | — | CN | disclosed |
| US-20130245013-A1 | STORAGE STABLE PERFUSION SOLUTION FOR DIHYDROPTERIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-8445675-B2 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| WO-2006018221-A1 | DIHYDROPTERIDINONE INFUSION SOLUTION HAVING A LONG SHELF LIFE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006018185-A2 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-23 | — | — | WO | disclosed |
| US-20060035903-A1 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | disclosed |
| US-20060025411-A1 | Methods for treating diseases or conditions using dihydropteridinone compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-02-02 | — | — | US | disclosed |
| EP-1599478-A1 | DIHYDROPTERIDINONES, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-6861422-B2 | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-01 | — | — | US | disclosed |
| US-20050014761-A1 | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | 2005-01-20 | — | — | US | disclosed |
| US-20050014760-A1 | Methods of treating diseases or conditions using dihydropteridinone compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004076454-A1 | DIHYDROPTERIDINONES, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-09-10 | — | — | WO | disclosed |
| US-20040176380-A1 | New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035903-A1 | Storage stable perfusion solution for dihydropteridinones | QDPR, F5, F12 | KMT2A 4810/4885ALDH1A1 1200/4885MEN1 1038/4885 |
| US-20040176380-A1 | New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | QDPR, DHPS, DRD5 | KMT2A 4752/4885ALDH1A1 608/4885MEN1 919/4885 |
| US-20050014760-A1 | Methods of treating diseases or conditions using dihydropteridinone compounds | QDPR, DHPS, DHFR | KMT2A 4527/4885ALDH1A1 742/4885MEN1 417/4885 |
| US-20060025411-A1 | Methods for treating diseases or conditions using dihydropteridinone compounds | QDPR, DHPS, DHFR | KMT2A 4518/4885ALDH1A1 603/4885MEN1 499/4885 |
| US-20050014761-A1 | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions | QDPR, DHPS, DHODH | KMT2A 4704/4885ALDH1A1 759/4885MEN1 690/4885 |
| US-20130245013-A1 | STORAGE STABLE PERFUSION SOLUTION FOR DIHYDROPTERIDINONES | QDPR, F5, F12 | KMT2A 4810/4885ALDH1A1 1200/4885MEN1 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.